Bracco Imaging’s VueJect Ultrasound Contrast System Wins FDA and Health Canada Approval

Bracco Imaging has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) and formal authorization from Health Canada for its proprietary VueJect contrast delivery system, according to industry announcements. The regulatory green lights mark a key operational milestone for the company’s expansion of contrast-enhanced ultrasound procedures in cardiology markets across North America.

Designed specifically to support cardiac imaging, the new device functions as a dedicated injector within Bracco’s broader ultrasound-enhancing agent ecosystem. Company executives noted that the system is engineered to streamline clinical workflows by administering agents such as Lumason and SonoVue in dilution during routine echocardiography procedures.

With North American clearances now finalized, leadership at Bracco Imaging plans to pursue additional international regulatory submissions to widen global access to the technology. The commercial rollout is expected to bring standardized contrast administration tools directly to cardiac sonographers and clinical teams.

Standardizing Contrast Administration in Cardiac Imaging

The introduction of the VueJect system addresses long-standing operational challenges in contrast-enhanced ultrasound, commonly known as CEUS. According to Applied Radiology, the device aims to minimize operator-to-operator variability during cardiac examinations, thereby ensuring more consistent enhancement levels throughout daily clinical workflows.

Robert Mitchell, Director, Ultrasound Platform Americas at Bracco Imaging, emphasized that the technology equips cardiac sonographers with a reliable, repeatable approach to contrast delivery. By removing manual discrepancies in preparation and administration, healthcare facilities can expect steadier diagnostic imaging results.

The device integrates directly into existing diagnostic suites as part of the company’s dedicated portfolio of ultrasound-enhancing agents. Luca Frazzoli, Global Head of Ultrasound at Bracco Imaging, pointed out that the injector’s ability to handle diluted doses of agents like Lumason and SonoVue makes it a versatile asset for busy echocardiography laboratories.

Global Strategy and Commercial Rollout

Securing regulatory permissions in both the United States and Canada forms the cornerstone of a wider corporate strategy. Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging, described the dual approvals as a major strategic milestone supporting the company’s ongoing investments in advanced ultrasound technologies worldwide.

As domestic commercialization efforts get underway in North America, regulatory teams are simultaneously preparing documentation for submission in various international markets. These upcoming filings form part of an organized push to expand the footprint of the company’s specialized ultrasound ecosystem.

Healthcare providers seeking further details on the rollout or technical specifications can monitor official updates through corporate announcements and upcoming medical device exhibitions where the hardware will be demonstrated to clinical professionals.